Shared from twixb · statnews.com

STAT+: Up and down the ladder: The latest comings and goings

statnews.com·Jun 12, 2026

The article highlights recent job changes in the pharmaceutical industry, including the hiring of Michelle Mellion as chief medical officer at AstronauTx, previously held roles at PepGen and EveryONE Medicines. It invites readers to share news about personnel changes in the sector.

The content provides no relevant insights or actionable takeaways specific to your interests in healthtech, biotech, digital health, or AI drug discovery. It primarily reports on personnel changes within the pharmaceutical industry.

Want more content like this?

twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.

Create Your Own →Explore Newsfeeds

More from Healthtech & Biotech News

Recent stories curated alongside this one.

medcitynews.com
Paul Markovich’s 4 Ideas to Reduce Healthcare Costs - MedCity News
Healthcare costs in the U.S. are rising unsustainably, prompting Paul Markovich, CEO of Ascendiun, to advocate for systemic reforms through a new policy movement called Worthy. Key proposals include implementing digital health records, shifting to outcome-based payment models, making prescription drugs more affordable, and placing healthcare organizations on a budget to control costs.
medcitynews.com
Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass - MedCity News
Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million to support its pipeline, which includes a gene therapy for Danon disease, a condition with no FDA-approved treatments. The sale reflects increasing demand for such vouchers, with prices rising from around $100 million in previous years.
endpts.com
Eli Lilly invests in startup Abridge for clinical trial recruitment
Eli Lilly has invested in health tech startup Abridge as it aims to enhance clinical trial recruitment and expand its presence in the life sciences sector.
endpts.com
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
Enliven Therapeutics has priced a $400 million offering, while Jazz Pharmaceuticals' drug Zepzelca has failed a confirmatory study.
statnews.com
STAT+: Prometheus raises $12 billion in capital for artificial engineers
Prometheus has successfully raised $12 billion to develop "artificial general engineers" in biopharma, while Abridge has formed partnerships with Eli Lilly and Nvidia to improve clinical trial recruitment. Additionally, a nonprofit organization has acquired a cancer drug for pediatric leukemia, intending to distribute it for free.

Browse all Healthtech & Biotech News →

STAT+: Up and down the ladder: The latest comings and goings

Want more content like this?

More from Healthtech & Biotech News

Paul Markovich’s 4 Ideas to Reduce Healthcare Costs - MedCity News

Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass - MedCity News

Eli Lilly invests in startup Abridge for clinical trial recruitment

Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study

STAT+: Prometheus raises $12 billion in capital for artificial engineers